17:33 EST TuHURA Biosciences (HURA) files $250M mixed securities shelf
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HURA:
- TuHURA Biosciences Plans Phase 2 Trial for TBS-2025
- TuHURA Biosciences Secures $3M Bridge Loan Agreement
- Tuhura Biosciences Advances in Merkel Cell Carcinoma Treatment Study
- Tuhura Biosciences’ Promising Phase 1 Trial: A Potential Game-Changer in Merkel Cell Carcinoma Treatment
- TuHURA Biosciences Extends Warrant Expiration to 2030